Insmed market cap INSM
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 3, 2026
- $23.7B
- Highest close in our data
- $44.3B
- Nov 2025
Insmed is worth $23.7B at the close on Nov 3, 2026, at $108.51 a share.
That is down 41% over the last year and up 499% over five years.
Its highest close in our data was $44.3B in Nov 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $23.9B | $20.4B | $37.8B | −37% |
| 2025 | $37.9B | $11.7B | $44.3B | +205% |
| 2024 | $12.5B | $3.3B | $13.5B | +181% |
| 2023 | $4.4B | $2.2B | $4.4B | +64% |
| 2022 | $2.7B | $2.2B | $3.3B | −16% |
| 2021 | $3.2B | $2.5B | $4.3B | −5% |
| 2020 | $3.4B | $1.3B | $4.1B | +60% |
| 2019 | $2.1B | $1.1B | $2.5B | +111% |
| 2018 | $1B | $903.5M | $2.4B | −58% |
| 2017 | $2.4B | $724.2M | $2.4B | +192% |
| 2016 | $818.6M | $585.4M | $993.8M | −27% |
| 2015 | $1.1B | $731.1M | $1.7B | +47% |
| 2014 | $763.4M | $464.3M | $829.5M | +14% |
| 2013 | $669.2M | $181.8M | $669.2M | +231% |
| 2012 | $201.9M | $67.1M | $250.5M | +167% |
| 2011 | $75.7M | $65.6M | $128.1M | n/a |
Against its peers
Companies in Biotechnology nearest Insmed's size, closest first, today.
| Company | Market cap |
|---|---|
| INSMInsmed | $23.7B |
| INCYIncyte | $24.3B |
| UTHRUnited Therapeutics | $25.9B |
| ALNYAlnylam Pharmaceuticals | $21.2B |
| EXELExelixis | $17.4B |
| NBIXNeurocrine Biosciences | $14.8B |
| HALOHalozyme Therapeutics | $14.6B |
| ONCBeOne Medicines | $40.2B |
| TECHBIO-TECHNE | $11.4B |
| RGENRepligen | $9.8B |
| KRYSKrystal Biotech | $8.8B |
| Peer median | $16.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Insmed
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.